Similar articles

• MAO inhibition and antidepressant activity.

  Feldstein A, Hoagland H, Rivera Oktem M, Freeman H. Feldstein A, et al. Int J Neuropsychiatry. 1965 Aug;1(4):384-7. Int J Neuropsychiatry. 1965. PMID: 5324597 Clinical Trial. No abstract available.
• Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid.

  Kennedy SH, Piran N, Garfinkel PE. Kennedy SH, et al. J Clin Psychopharmacol. 1985 Oct;5(5):279-85. doi: 10.1097/00004714-198510000-00005. J Clin Psychopharmacol. 1985. PMID: 3862680
• Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients.

  Carman JS, Gillin JC, Murphy DL, Weinberger DR, Kleinman JE, Bigelow LB, Wyatt RJ. Carman JS, et al. Commun Psychopharmacol. 1978;2(6):513-23. Commun Psychopharmacol. 1978. PMID: 371909 Clinical Trial. No abstract available.
• Pharmacotherapy of anorexia nervosa and bulimia.

  Herzog DB. Herzog DB. Pediatr Ann. 1984 Dec;13(12):915, 918-9, 923. Pediatr Ann. 1984. PMID: 6395077 Review. No abstract available.
• [Are psychotropic drugs necessary for the treatment of anorexia and bulimia nervosa?].

  Thiel A. Thiel A. Psychother Psychosom Med Psychol. 1997 Sep-Oct;47(9-10):332-45. Psychother Psychosom Med Psychol. 1997. PMID: 9411463 Review. German.